Acrux Full Year 2023 Earnings: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

Acrux (ASX:ACR) Full Year 2023 Results

Key Financial Results

• Revenue: AU$8.43m (up 390% from FY 2022).
• Net loss: AU$764.0k (loss narrowed by 92% from FY 2022).
• AU$0.003 loss per share (improved from AU$0.035 loss in FY 2022).

ACR Post-Clinical Trial Products

• Pre-registration: 3.
• Approved (during full year): 1.
• Launched (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Acrux shares are down 10% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Acrux (at least 1 which is concerning), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.